
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics is generating immense potential in the biotech industry with their innovative TANGO platform and drug candidates such as zorevunersen and STK-002. These drugs have shown promising results in preclinical and early clinical trials in treating genetic diseases, and the company's partnerships with other biotech companies further solidify their position in the market. With a strong cash position and a potential for disease modification, Stoke has the capability to address a broad unmet need in the genetic disease space.
Bears say
Stoke Therapeutics is facing potential challenges in successfully developing and commercializing its RNA medicine approach, with limited data from its early programs. Its financial results show a significant increase in expenses, with continued reliance on third-party data and the need for additional capital to become profitable. The company also faces risks related to potential patent disputes and the volatility of its stock price due to a significant stake held by Skorpios Trust. Adherence to appropriate pricing strategies will be crucial in ensuring market acceptance for its product candidates and maintaining adequate coverage and reimbursement.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares